To prevent the destruction of tissues owing to excessive and/or inappropriate immune
responses, immune cells are under strict check by various regulatory mechanisms at …

Sarcomas are heterogeneous and clinically challenging soft tissue and bone cancers.
Although constituting only 1% of all human malignancies, sarcomas represent the second …

In one decade, immunotherapy based on immune checkpoint blockades (ICBs) has become
a new pillar of cancer treatment following surgery, radiation, chemotherapy, and targeted …

Cancer is a critical issue globally with high incidence and mortality, imposing great burden
on the society. Although great progress has been made in immunotherapy based on …

Anti-PD-(L) 1 therapies yield a disappointing response rate of 15% across soft-tissue
sarcomas, even if some subtypes benefit more than others. The proportions of TAMs and …

Background Fibrinogen-like protein 1 (FGL1)—Lymphocyte activating gene 3 (LAG-3)
pathway is a promising immunotherapeutic target and has synergistic effect with …

Cuproptosis, a new type of programmed cell death, is involved in the development and
progression of malignancies. The study of cuproptosis-associated long non-coding RNAs …

Simple Summary Patients with chronic lymphocytic leukemia (CLL), the most frequent B cell
malignancy in western countries, develop a progressive immunosuppression, leading to …

Several preclinical studies demonstrate that antitumor efficacy of programmed cell death-1
(PD-1)/programmed death-ligand 1 (PD-L1) blockade can be improved by combination with …

Osteosarcoma (OS) is the most common primary malignant bone sarcoma mainly affecting
adolescents and young adults, which often progresses to pulmonary metastasis and leads to …